Investors Have Low Expectations for Biogen (BIIB) ALS Phase III Data Implying Good Risk/Reward - Jefferies
Tweet Send to a Friend
Jefferies analyst Michael Yee reiterated a Buy rating and $500.00 price target on Biogen (NASDAQ: BIIB) on the belief that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
